| 新药RRx-001临床研究进展 |
| 投稿时间：2024-02-23 修订日期：2024-03-29 点此下载全文 |
| 引用本文： |
| 摘要点击次数: 409 |
| 全文下载次数: 0 |
|
|
| 中文摘要:恶性肿瘤、神经退行性疾病、血管性疾病等一直是临床治疗的难点，由于这些疾病的发病机制复杂性，找寻疗效高且副作用小的药物是治疗药物研究的热点。RRx-001作为潜在首创（First-In-Class, FIC）的小分子药物，有望成为肿瘤免疫治疗、放化疗增敏和保护的重要临床一线药物。目前，RRx-001已进入III期临床研究阶段，II期临床试验数据证实了RRx-001临床安全性和有效性，并且发现与临床肿瘤治疗一线药物联合用药的优越性。本文总结了RRx-001的作用机制研究新进展和主要临床试验研究结果，对后续针对RRx-001的优化设计和临床应用具有一定的指导意义。 |
| 中文关键词:RRx-001 肿瘤免疫 综述 临床试验 |
| |
| Clinical research progress of RRx-001 |
|
|
| Abstract:It is difficult to treat malignant tumors, neurodegenerative diseases, and vascular diseases. For pathogenesis complexity of these diseases, researchers make great efforts to find more drugs with high efficacy and low side effects. As a potential first-in-class drug, RRx-001 is expected to be an important first-line drug in tumor immunology, radiosensitizer and radio protecter. Currently, RRx-001 has entered phase III clinical trials. The data of the phase II clinical trials have been demonstrated its safety and effectivity as a single agent and in combination with first-line clinical drugs. This review summarizes the novel mechanisms of RRx-001 and the result of main clinical trials. It will be valuable to further optimization and clinical application. |
| keywords:RRx-001 Tumor immunology Review Clinical trials |
| 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
